您好，欢迎光临世界标品！ 登录 注册（订药物标准品请用邮件联系我们）

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索（中英文）：
世界各国官方药品目录搜索（英文）：
世界标品医药知识搜索（中英文）：

美国药房|加拿大药房|英国药房|瑞士药房|澳大利亚药房|新西兰药房|香港药房|印度药房|新加坡药房|俄罗斯药房|法律的依据
日本药房|德国药房|孟加拉药房|巴西药房|欧洲共同体药房|土耳其药房|以色列药房|法国药房|罗马尼亚药房|墨西哥药房|爱尔兰药房
荷兰药房|意大利药房|保加利亚药房|南非药房|芬兰药房|挪威药房
联系方式
国内客服电话：
国际免费电话：

咨询邮箱：
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 糖尿病->2型糖尿病
处方药:处方药
包装规格: 12.5-30毫克/片 30片/盒
计价单位: 盒
   
生产厂家中文参考译名:
武田药品有限公司
生产厂家英文名:
 Takeda
该药品相关信息网址1:
 http://www.news-medical.net/news/20130128/FDA-approves-Takedae28099s-NESINA-OSENI-and-KAZANO-for-treatment-of-type-2-diabetes.aspx
该药品相关信息网址2:
 http://www.rxlist.com/oseni-drug.htm
该药品相关信息网址3:
 http://www.drugs.com/oseni.html
 原产地英文商品名:
 OSENI 12.5-30 MG 30 TABLETS
原产地英文药品名:
 ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL
中文参考商品译名:
 OSENI 12.5-30毫克/片 30片/盒
中文参考药品译名:
 苯甲酸阿格列汀/盐酸吡格列酮
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
 Type 2 Diabetes
 临床试验期:
 完成
中文适应病症参考翻译1:
 2型糖尿病
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（201411504191811.pdf）的“原文Priscribing Information”为准

Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

"Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience," said Douglas Cole , president, Takeda Pharmaceuticals U.S.A., Inc. "Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."

NESINA is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). OSENI, which combines alogliptin with pioglitazone, is the first product in the U.S. to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. KAZANO combines alogliptin with metformin HCl, a widely used anti-diabetes medication, in a single tablet.

OSENI tablets contain 2 oral antihyperglycemic drugs used in the management of type 2 diabetes: alogliptin and pioglitazone.
更新日期: 2013-07-10
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间：太平洋时间18:00-24:00
国内客服电话：     国际免费电话：
友情提示：以上电话为免费电话，无需您承担任何费用，世界标品提供中文客服，请您放心拨打！
电子邮箱：sciteck.hongkong@gmail.com, 15901965168@163.com